These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11227392)

  • 21. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A; Davis C; Mulinari S
    PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The characteristics of regulation of pharmaceutical market of the Eurasian Economical Union].
    Marseva TG; Voblaia IN; Seifieva EN
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2019 Sep; 27(5):841-846. PubMed ID: 31765534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical policies in European countries.
    Barros PP
    Adv Health Econ Health Serv Res; 2010; 22():3-27. PubMed ID: 20575226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pros and cons of a single 'Euro-price' for drugs.
    Towse A
    Pharmacoeconomics; 1998 Mar; 13(3):271-6. PubMed ID: 10178652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Causes of drug shortages in the legal pharmaceutical framework.
    De Weerdt E; Simoens S; Hombroeckx L; Casteels M; Huys I
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):251-8. PubMed ID: 25591547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 30. [The European Union and drugs].
    Viala G; Campion MD
    Ann Pharm Fr; 1995; 53(4):184-7. PubMed ID: 7574273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective view on European pharmaceutical research and development. Policy options to reduce fragmentation and increase competitiveness.
    Kanavos P
    Pharmacoeconomics; 1998 Feb; 13(2):181-90. PubMed ID: 10178646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. European registration: today, tomorrow, and beyond.
    Currie WJ
    J Clin Pharmacol; 1990 May; 30(5):386-9. PubMed ID: 2347953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restrictions of the sale of pharmaceuticals and medical devices such as contact lenses over the internet and the free movement of goods.
    de Sadeleer N
    Eur J Health Law; 2012 Mar; 19(1):3-28. PubMed ID: 22428387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 37. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European regulatory policies on medicines and public health needs.
    Li Bassi L; Bertele V; Garattini S
    Eur J Public Health; 2003 Sep; 13(3):246-51. PubMed ID: 14533728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.